NEW YORK, March 12, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
The investigation concerns whether ACADIA and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On March 11, 2015, the Company announced that it would delay submitting a new-drug application for Nuplazid until later this year. The company also said that Chief Executive Uli Hacksell is retiring.
On this news, shares of ACADIA fell $10.18 per share to $34.64, or more than 22.64%, on March 12, 2015.
The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-acadia-pharmaceuticals-inc---acad-300049815.html
SOURCE Pomerantz LLP